Venus Remedies Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 10 per equity share.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Venus Remedies Limited's Board meeting on May 26, 2026 recommended a final dividend of Rs. 10 per equity share (100% on face value of Rs. 10) for FY 2025-26, subject to shareholder approval at the 37th AGM on August 20, 2026. The company reported strong audited results with standalone revenue from operations of Rs. 768.73 crore (up 19% YoY) and net profit of Rs. 99.31 crore (up 89% YoY). Consolidated net profit stood at Rs. 102.78 crore, nearly doubling from Rs. 45.31 crore in the previous year. Consolidated EPS increased to Rs. 76.89 from Rs. 33.89. The record date for dividend eligibility is August 7, 2026. Key director appointments include Mrs. Savita Gupta, Dr. Gurminder Singh Bedi, Dr. Madhavi Prabhudkar, and Mr. Saransh Chaudhary. The company also adopted new MOA and AOA aligned with Companies Act 2013.
Strong financial performance with near-doubling of net profit and a 100% dividend payout signals confidence in the company's growth trajectory, which should be positive for shareholders ahead of the AGM approval.